Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Stamford; Andrew
Address:
Chatham Township, NJ
No. of patents:
22
Patents:












Patent Number Title Of Patent Date Issued
8278334 Cyclic amine BACE-1 inhibitors having a benzamide substituent October 2, 2012
Disclosed are compounds of the formula ##STR00001## or a pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1 is ##STR00002## R is --C(O)--N(R.sup.27)(R.sup.28) or ##STR00003## and the remaining variables are as defined in the specification. Also disclose
8183252 Heterocyclic aspartyl protease inhibitors May 22, 2012
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.s
8168641 Aspartyl protease inhibitors May 1, 2012
Disclosed are compounds of formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, U, W, X, R.sup.1, R.sup.2, R.sup.6, R.sup.7, R.sup.30 and R.sup.31 are as described above in the specification. Also disclosed is the method of inh
8110682 Preparation and use of compounds as aspartyl protease inhibitors February 7, 2012
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein A is a bond, --C(O)--, or --C(R.sup.3')(R.sup.4')--; X is --N(R.sup.1)-- or --C(R.sup.6)(R.sup.7)--; Y is --S(O).sub.2--, --C(.dbd.O)
8093254 Aspartyl protease inhibitors January 10, 2012
Disclosed are compounds of formula I (Chemical formula should be inserted here as it appears on abstract in paper form) Formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.14, V, W, X, Y, Z,
7973067 Heterocyclic aspartyl protease inhibitors July 5, 2011
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.s
7910590 Cyclic amine bace-1 inhibitors having a heterocyclic substituent March 22, 2011
Disclosed are novel compounds of the formula ##STR00001## or a pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1 is ##STR00002## X is --O--, --C(R .sup.14).sub.2-- or --N(R)--; Z is --C(R.sup.14).sub.2-- or --N(R)--; t is 0, 1, 2 or 3; each R and R.sup.2 is
7868000 Aspartyl protease inhibitors January 11, 2011
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein j, k, U, W, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7 and R.sup.7a are as described above in the specification.Also disclosed
7812013 Macrocyclic heterocyclic aspartyl protease inhibitors October 12, 2010
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt, solvate or ester thereof, wherein U, W, X, L, Y, M, Z, c, d, e, f, g, h, s, t, R.sup.1, R.sup.2, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13,
7763609 Heterocyclic aspartyl protease inhibitors July 27, 2010
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.sup.5)
7759354 Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof July 20, 2010
The present application provides compounds of the Formula: ##STR00001## and stereoisomers, tautomers, or pharmaceutically acceptable salts and solvates thereof, wherein U, W, R, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 in each formula (when present) are as defined in the specification, and
7759353 Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods July 20, 2010
Disclosed are certain substituted spiro iminopyrimidinones and other compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein U, W, A, R, R.sup.1, R.sup.2, R.sup.6a and R.sup.7, are as defined in the specifi
7713985 Adenosine A.sub.a2 receptor antagonists May 11, 2010
Compounds having the structural formula I ##STR00001## or a pharmaceutically acceptable salt thereof, wherein: X.sup.1 and X.sup.2 are 1-3 substituents independently selected from the group consisting of H, alkyl, halo, --CF.sub.3, --OCF.sub.3, alkoxy, --OH and --CN; n is 0, 1 or
7709492 Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A.sub.2a receptor antagonists May 4, 2010
Compounds having the structural formula I ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H,
7700603 Heterocyclic aspartyl protease inhibitors April 20, 2010
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.sup.5)
7662816 Cyclic amine BACE-1 inhibitors having a benzamide substituent February 16, 2010
Disclosed are compounds of the formula ##STR00001## or a pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1 is ##STR00002## R is --C(O)--N(R.sup.27)(R.sup.28) or ##STR00003## and the remaining variables are as defined in the specification.Also disclosed are
7598250 Cyclic amine BACE-1 inhibitors having a heterocyclic substituent October 6, 2009
Disclosed are novel compounds of the formula ##STR00001## or a pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1 is ##STR00002## X is --O--, --C(R.sup.14).sub.2-- or --N(R)--; Z is --C(R.sup.14).sub.2-- or --N(R)--; t is 0, 1, 2 or 3; each R and R.sup.2 is
7592348 Heterocyclic aspartyl protease inhibitors September 22, 2009
Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, --C(.dbd.S)--, --S(O)--, --S(O).sub.2--, --C(.dbd.O)--, --O--, --C(R.sup.6)(R.sup.7)--, --N(R.sup.5)-- or --C(.dbd.N(R.sup.5)
7368449 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A.sub. May 6, 2008
Compounds having the structural formula I ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R is ##STR00002## R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H, alkyl or alkoxyalkyl; R.sup.6 is H, alkyl, hydroxyalkyl or --CH.sub.2F; R.sup.7, R.sup.8 and R.s
7312223 Metabolite of xanthine Phosphodiesterase 5 inhibitor and derivatives thereof useful for treatmen December 25, 2007
The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structure ##STR00001## derivatives, and formulations thereof, and processes for preparing the same.Further disclosed are methods of treating a physiological disord
7268141 Xanthine phosphodiesterase V inhibitors September 11, 2007
A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: ##STR00001## For example, a representative compound of the inve
6897217 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a recepto May 24, 2005
Compounds having the structural formula I ##STR1##or a pharmaceutically acceptable salt thereof, wherein R is ##STR2## R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H, alkyl or alkoxyalkyl; R.sup.6 is H, alkyl, hydroxyalkyl or --CH.sub.2 F; R.sup.7, R.sup.8 and R.sup.9 are H










 
 
  Recently Added Patents
Audio and music data transmission medium and transmission protocol
Apparatus and method for evaluating an activity distribution, and irradiation system
Wrench
Method for radiation sterilization of medical devices
Processing color and panchromatic pixels
Cryptographically generated addresses using backward key chain for secure route optimization in mobile internet protocol
Generating a network map
  Randomly Featured Patents
Tolerizing and desensitizing compounds, compositions and methods of treatment against dermatological conditions caused by allergens from plants and trees of the Anacardiaceae and Ginkgoaceae f
Flat panel emissive display with redundant circuit
Active pulse monitoring in a chemical reactor
Apparatus and methods for treating allograft products
Bone marrow infusion chamber and method
Methods of isolating specific compounds from supramammary lymph node tissue
Video camera apparatus using a plurality of imaging devices
I-NRZI modulator using parallel-bit-word at precoder, as for inclusion in magnetic recording apparatus
Headphones
Radiation delivery catheters and dosimetry methods